Global Non-small Cell Lung Cancer Treatment Market Outlook, Trends And Future Opportunities (2023-2030)

Global Non-small Cell Lung Cancer Treatment Market Outlook, Trends And Future Opportunities (2023-2030)

Global Non-small Cell Lung Cancer Treatment Market, Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Others), Marketed Brand (Bevacizumab (Avastin), Necitumumab (Portrazza), Ramucirumab (Cyramza), Nivolumab (Opdivo), Atezolizumab (Tecentriq), Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) The report offers a comprehensive view of the market from supply as well as demand side to help take informed decisions.

  • Published On: Sep 2023
  • Report ID: IDA38
  • Region: Global
  • Format: PDF/EXCEL

Lung cancer originates in the lungs, and there are two major types of lung cancer which are; non-small cell lung cancer, and small cell lung cancer. People with smoking habit have greatest risk of developing lung cancer. Second hand smoke, family history, and exposure to certain toxins are few of the other reasons behind development of lung cancer. 
Non-small cell lung cancer is a common form of lung cancer and subcategorized into squamous cell carcinoma, adenocarcinoma and large cell carcinoma. Diagnosis of lung cancer includes imaging, biopsy, and treatment includes radiotherapy, surgery, chemotherapy, immunotherapy, and targeted drug therapy among others. 

Market Drivers and Restraints:

  • Increasing prevalence of lung cancer
    • According to American Cancer Society (ASC), in 2022, there were ~236,740 new cases of lung cancer (117,910 in men and 118,830 in women) in the US.
    • Furthermore, approximately 84% of the lung cancer cases are of NSCLC, and rest 14% are of small cell lung cancer
  • Global Non-small cell lung cancer market has a wide and robust research and development pipeline. Leading as well as small to medium size organizations are developing novel therapies for the treatment of the disease.
  • Global Non-small cell lung cancer treatment landscape has seen several regulatory drug approvals, and products launches over past few years which has fuelled growth of the global Non-small cell lung cancer market.

Non-small Cell Lung Cancer Epidemiology:

Geography

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

US

Full data, forecast assumptions, and estimates will be provided in the full report.

EU5

Japan

Global Non-small Cell Lung Cancer Treatment Market accounted for US$ 24.1 Bn in 2022 and is expected to witness a CAGR of 8.9% over the forecast period (2022-2030) to reach US$ 47.5 Bn by 2030

Competitive Landscape:

The global non-small cell lung cancer treatment market is fairly consolidated with a few multinational corporations dominating in the industry. Key companies operating in the market are well-equipped with large manufacturing facilities and they are engaged in various research and development activities. 

We employ tools and techniques such as PEST analysis, SWOT analysis, PORTER’s analysis, BCG matrix to provide competitive and market intelligence.

Some of the prominent players operating in the market are:

  • Pfizer Inc.
  • AstraZeneca plc
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • Boehringer Ingelheim GMBH
  • Novartis International AG
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Amgen, Inc.

Key Insights

Description

The market size in 2021

USD 22.1 Billion 

CAGR (2021 - 2030)

8.9%

The revenue forecast in 2030

USD 47.5 Billion

Base year for estimation

2021 

Historical data

2017-2020

Forecast period

2022-2030

Quantitative units

Revenue in USD Billion, and CAGR from 2021 to 2030

Market segments

Treatment Type, Marketed Brand, Distribution Channel, Region

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

Market Drivers

  • Increasing prevalence of lung cancer
  • Products launches

Market Restraints

  • High treatment costs
  • Failure of pipeline drugs to advance in clinical trials

Competitive Landscape

Eli Lilly and Company, Merck & Co., Inc., Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim GMBH, Novartis International AG, Bristol-Myers Squibb Company, Johnson & Johnson, Amgen, Inc.

Segments covered in the global non-small cell lung cancer treatment market report:

The global non-small cell lung cancer treatment market is segmented based on treatment type, marketed brand , distribution channel, and region as follows:

  • Treatment Type (Revenue, USD Billion; 2022–2030)
    • Chemotherapy
    • Targeted Therapy
    • Immunotherapy
    • Others
  • Marketed Brand (Revenue, USD Billion; 2022–2030)
    • Bevacizumab (Avastin)
    • Necitumumab (Portrazza)
    • Ramucirumab (Cyramza)
    • Nivolumab (Opdivo)
    • Atezolizumab (Tecentriq)
    • Others
  • Distribution Channel (Revenue, USD Billion; 2022–2030)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Region (Revenue, USD Billion; 2022–2030)
    • North America 
      • U.S.
      • Canada
    • Europe 
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific 
      • China
      • Japan
      • South Korea
      • India
      • ASEAN
      • Rest of APAC
    • Latin America 
      • Brazil
      • Mexico
      • Rest of LATAM
    • Middle East & Africa 
      • Saudi Arabia
      • UAE
      • Rest of MEA

Frequently Asked Questions

The current market size of the non-small cell lung cancer (NSCLC) treatment industry is estimated to be US$ 26.2 billion in 2023.

Rising prevalence of NSCLC, increasing demand for targeted therapies, and technological advancements are contributing significantly to the growth of the Non-small Cell Lung Cancer Treatment market.

The key factors hampering the growth of the Non-small Cell Lung Cancer Treatment Market are high cost of treatment and limited access to care in developing countries.

The leading component segment in the Non-small Cell Lung Cancer Treatment Market is targeted therapies.

AstraZeneca, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Johnson & Johnson, Merck, Novartis, Pfizer, Takeda are the major players operating in the Non-small Cell Lung Cancer Treatment Market.

The non-small cell lung cancer treatment market is expected to grow at a CAGR of 8.9% and reach a market size of US$ 47.5 billion by 2030.
Select License Type
Download FREE Sample Customize As Per Need Buy Now